The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses the primary endpoint analysis of the Phase II CLL-RT1 trial (NCT04271956) which investigated the safety and efficacy of a treatment regimen of tislelizumab (a PD1 inhibitor) and zanubrutinib (a BTK inhibitor) in patients with Richter’s transformation (RT). The treatment was well tolerated by patients and the responses observed in the trial were encouraging, especially as prognosis in this patient population has historically been poor. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AstraZeneca, BeiGene, Gilead, Janssen, Lilly, MSD, Abbvie
Honoraria: AstraZeneca, BeiGene, MSD, F. Hoffmann-La Roche Ltd, Abbvie
Research Funding: AstraZeneca, BeiGene, Gilead, Janssen, F. Hoffmann-La Roche Ltd, Abbvie
Speakers Bureau:AstraZeneca, BeiGene, Janssen, Lilly, MSD, F. Hoffmann-La Roche Ltd, Abbvie
